Show simple item record

dc.contributor.authorGautschi, O
dc.contributor.authorMilia, J
dc.contributor.authorFilleron, T
dc.contributor.authorWolf, J
dc.contributor.authorCarbone, DP
dc.contributor.authorOwen, D
dc.contributor.authorCamidge, R
dc.contributor.authorNarayanan, V
dc.contributor.authorDoebele, RC
dc.contributor.authorBesse, B
dc.contributor.authorRemon-Masip, J
dc.contributor.authorJanne, PA
dc.contributor.authorAwad, MM
dc.contributor.authorPeled, N
dc.contributor.authorByoung, C-C
dc.contributor.authorKarp, DD
dc.contributor.authorVan Den Heuvel, M
dc.contributor.authorWakelee, HA
dc.contributor.authorNeal, JW
dc.contributor.authorMok, TSK
dc.contributor.authorYang, JCH
dc.contributor.authorOu, S-HI
dc.contributor.authorPall, G
dc.contributor.authorFroesch, P
dc.contributor.authorZalcman, G
dc.contributor.authorGandara, DR
dc.contributor.authorRiess, JW
dc.contributor.authorVelcheti, V
dc.contributor.authorZeidler, K
dc.contributor.authorDiebold, J
dc.contributor.authorFrüh, M
dc.contributor.authorMichels, S
dc.contributor.authorMonnet, I
dc.contributor.authorPopat, S
dc.contributor.authorRosell, R
dc.contributor.authorKarachaliou, N
dc.contributor.authorRothschild, SI
dc.contributor.authorShih, J-Y
dc.contributor.authorWarth, A
dc.contributor.authorMuley, T
dc.contributor.authorCabillic, F
dc.contributor.authorMazières, J
dc.contributor.authorDrilon, A
dc.date.accessioned2018-03-05T15:02:40Z
dc.date.issued2017-05
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 35 (13), pp. 1403 - 1410
dc.identifier.issn0732-183X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1555
dc.identifier.eissn1527-7755
dc.identifier.doi10.1200/jco.2016.70.9352
dc.description.abstractPurpose In addition to prospective trials for non-small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response to targeted therapies. Here, we present the results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to our knowledge, on outcomes of RET-directed therapy thus far. Methods A global, multicenter network of thoracic oncologists identified patients with pathologically confirmed NSCLC that harbored a RET rearrangement. Molecular profiling was performed locally by reverse transcriptase polymerase chain reaction, fluorescence in situ hybridization, or next-generation sequencing. Anonymized data-clinical, pathologic, and molecular features-were collected centrally and analyzed by an independent statistician. Best response to RET tyrosine kinase inhibition administered outside of a clinical trial was determined by RECIST v1.1. Results By April 2016, 165 patients with RET-rearranged NSCLC from 29 centers across Europe, Asia, and the United States were accrued. Median age was 61 years (range, 29 to 89 years). The majority of patients were never smokers (63%) with lung adenocarcinomas (98%) and advanced disease (91%). The most frequent rearrangement was KIF5B-RET (72%). Of those patients, 53 received one or more RET tyrosine kinase inhibitors in sequence: cabozantinib (21 patients), vandetanib (11 patients), sunitinib (10 patients), sorafenib (two patients), alectinib (two patients), lenvatinib (two patients), nintedanib (two patients), ponatinib (two patients), and regorafenib (one patient). The rate of any complete or partial response to cabozantinib, vandetanib, and sunitinib was 37%, 18%, and 22%, respectively. Further responses were observed with lenvantinib and nintedanib. Median progression-free survival was 2.3 months (95% CI, 1.6 to 5.0 months), and median overall survival was 6.8 months (95% CI, 3.9 to 14.3 months). Conclusion Available multikinase inhibitors had limited activity in patients with RET-rearranged NSCLC in this retrospective study. Further investigation of the biology of RET-rearranged lung cancers and identification of new targeted therapeutics will be required to improve outcomes for these patients.
dc.formatPrint-Electronic
dc.format.extent1403 - 1410
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectLung Neoplasms
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectProtein Kinase Inhibitors
dc.subjectTreatment Outcome
dc.subjectRegistries
dc.subjectProspective Studies
dc.subjectGene Rearrangement
dc.subjectInternational Cooperation
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectProto-Oncogene Proteins c-ret
dc.subjectMolecular Targeted Therapy
dc.titleTargeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
dc.typeJournal Article
rioxxterms.versionofrecord10.1200/jco.2016.70.9352
rioxxterms.licenseref.startdate2017-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of clinical oncology : official journal of the American Society of Clinical Oncology
pubs.issue13
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume35
pubs.embargo.termsNot known
icr.researchteamThoracic Oncologyen_US
dc.contributor.icrauthorPopat, Sanjayen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record